Latest Conference Articles

In early findings, the antibody drug conjugate created strong responses in multiple tumor types where patients have unmet need.

Bhagirathbhai R. Dholaria, MD, assistant professor of medicine in the Department of Hematology-Oncology at Vanderbilt University Medical Center, discussed findings from the phase 2 TRiMM-2 trial of talquetamab plus daratumumab in multiple myeloma.

Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study of social determinants of health in the context of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.

The confirmatory trial showed limited side effects relative to physician's choice of chemotherapy.

Roy S. Herbst, MD, PhD, deputy director of Yale Cancer Center and lead investigator for ADAURA, said the results erase any doubts about the use of osimertinib in early non–small cell lung cancer (NSCLC) for patients with EGFR mutations.

The landmark trial harmonized treatment between adult and pediatric patients with classic Hodgkin lymphoma, who historically have received different chemotherapy regimens; young patients have received more treatment with radiation.

Combining talquetamab and daratumumab could create a synergy to get more from talquetamab to attack multiple myeloma.

"It's really important that oncologists are on level footing along with the rest of their medical peers," said Samyukta Mullangi, MD, MBA, incoming medical director at Thyme Care.

Interim findings from the DUO-O trial could signal new options for women diagnosed with ovarian cancer at later stages who do not have a BRCA mutation.

Surya Bhatt, MD, associate professor of medicine at University of Alabama at Birmingham, talks about a new trial in which dupilumab was used in patients with chronic obstructive pulmonary disease (COPD) with frequent exacerbations and type 2 inflammation.

The trial included patients with earlier stage disease who are normally considered lower risk than the high-risk population.

The 2023 European Hematology Association (EHA) Congress, convening virtually and in Frankfurt, Germany, from June 8-11, 2023, will feature cutting-edge findings in oncology and hematology, with a special focus on incorporating patient-reported outcomes and real-world data.

Attendees will gain insight into the future of multiple myeloma (MM) therapies and updates on pivotal clinical trials at the 2023 European Hematology Association (EHA) Congress, according to Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation.

The SLEEP 2023 conference will be held in Indianapolis from June 3 to June 7 and promises to feature topics including sleep health disparities, hypersomnia, geriatric medicine, and new technologies.

In this preview interview for SLEEP 2023, Rebecca Spencer, PhD, chair of the Associated Professional Sleep Societies Program Committee, highlights how bringing patients and clinicians together can inspire new ideas in sleep medicine.

The cancer care community descends on Chicago this weekend for the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO). This year’s theme, “Partnering With Patients: The Cornerstone of Cancer Care and Research,” highlights how recent advances make interactions between clinicians and patients more important than ever, as shared decision-making must be the foundation of the care journey.

Lalan Wilfong, MD, senior vice president of payer and care transformation at The US Oncology Network, shared insight into lessons learned from the Oncology Care Model (OCM) and looked ahead to the Enhancing Oncology Model (EOM) ahead of a panel discussion at the 2023 ASCO Annual Meeting.

Andrew Evens, DO, MBA, MSc, associate director for clinical services at Rutgers Cancer Institute, discussed the ways in which SWOG S1826 trial results will build on current knowledge of Hodgkin lymphoma treatment.

Chitra Lal, MD, D-ABSM, FCCP, FAASM, FACP, ATSF, professor of medicine at Medical University of South Carolina, says that the screening threshold for obstructive sleep apnea (OSA) should be low because 70% to 75% of patients with mild cognitive impairment have sleep apnea.

Debra Boyer, MD, pediatric pulmonologist at Nationwide Children’s Hospital and co-chair of the American Thoracic Society International Conference Committee says that even though there are strides to be made in pediatric pulmonology, treatments for children with diseases, such as cystic fibrosis, have improved.

Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, says that since sleep disorders are common, it’s important to consider that sleep can be a separate symptom from epilepsy.

A range of posters presented at the 2023 American Thoracic Society (ATS) International Conference highlighted a plethora of risk factors for pulmonary conditions in adulthood outside of tobacco smoking history.

A symposium at the 2023 American Thoracic Society International Conference highlighted common comorbidities that warrant consideration in patients who present with chronic obstructive pulmonary disease (COPD).

Franco Laghi, MD, a professor and pulmonologist affiliated with Loyola University Medical Center as well as the Edward Hines, Jr. Veterans Affairs Hospital in Maywood, Illinois, discussed the use of home-based exercise rehabilitation programs for veterans with long COVID-19, and patient reluctance to come to a medical facility during the pandemic.

Chitra Lal, MD, D-ABSM, FCCP, FAASM, FACP, ATSF, professor of medicine at Medical University of South Carolina, talks about how there might be a link between obstructive sleep apnea (OSA) and Alzheimer disease (AD), and that treating sleep apnea early and aggressively may help prevent AD development.

A symposium at the 2023 American Thoracic Society (ATS) International Conference featured research on predictors of chronic obstructive pulmonary disease (COPD) occurrence and disease progression.

Anna E. Mullins, PhD, assistant professor at the Icahn School of Medicine at Mount Sinai, discusses the necessity of awareness of how health issues can present in World Trade Center (WTC) responders.

Posters presented at the 2023 American Thoracic Society International Conference called for improvements in care for chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.